Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12943005 | 0.85 | CYP2D6 (0.44) | LTA4HKCNH2CYP2D6ALDH1A1CYP2C9 | |
| SCHEMBL13541808 | 0.84 | LTA4H (0.41) | LTA4HKCNH2CYP2C19CYP3A4TSHR | |
| SCHEMBL10025503 | 0.84 | LTA4H (0.42) | LTA4HKCNH2HRH3MAOAMAOB | |
| SCHEMBL10025516 | 0.83 | LTA4H (0.44) | LTA4HKCNH2MEN1HRH3MAOA | |
| SCHEMBL12943133 | 0.82 | DRD2 (0.43) | LTA4HKCNH2 | |
| SCHEMBL12842023 | 0.79 | OPRL1 (0.41) | LTA4HKCNH2 | |
| SCHEMBL296525 | 0.75 | L3MBTL1 (0.43) | LTA4HKCNH2MEN1KMT2A | |
| SCHEMBL1161004 | 0.74 | LTA4H (0.44) | LTA4HKCNH2KMT2ACYP2D6 | |
| SCHEMBL8114517 | 0.74 | HRH3 (0.46) | KCNH2CYP2C19MEN1KMT2ACYP2D6 | |
| SCHEMBL6941588 | 0.74 | HRH3 (0.46) | KCNH2CYP2C19MEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | LTA4H 1712/4885KCNH2 2366/4885CYP2C19 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.